In xenograft models of aggressive B-cell lymphoma, the coinjection of this stabilized version of IL-15 together with CD19-specific CAR-T cells augmented CAR-T-cell performance eventuating in the longer survival of tumor-bearing mice [49]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.